Our Research

Showing all research programs


Minimal Residual Disease

Group Leader : Dr Rosemary Sutton
About a fifth of children initially cured of acute lymphoblastic leukaemia (ALL), later suffer a relapse due to the persistence of small numbers of cancer cells throughout treatment (‘minimal residual disease’ or MRD). Our research focuses on seeing MRD testing become part of the routine clinical management of all children with ALL ...
Rosemary Sutton

Molecular Carcinogenesis

Group Leader : Prof Glenn Marshall
The Molecular Carcinogenesis program aims to improve our understanding of the molecules and processes that initiate childhood cancer as currently very little is known about the factors that lead to the development of cancer in children ...
Glenn Marshall

Molecular Diagnostics

Group Leader : Prof Murray Norris
The Molecular Diagnostics program uses molecular genetics techniques to improve the diagnosis and risk classification of childhood cancers including leukaemia and neuroblastoma ...
Murray Norris

Pancreatic Cancer Translational Research

Group Leader : A/Prof Phoebe Phillips
Pancreatic cancer claims five Australian lives every day and is one of the nation’s most lethal diseases. Despite aggressive treatment regimes, there has been no improvement in patient survival in the last decade. Evidence suggests that targeting cancer cells alone is not enough. The overall aim of the Pancreatic Cancer Translational Research group is to therapeutically target tumour cells and stromal pancreatic stellate cells (PSCs) which both contribute to chemoresistance in pancreatic cancer. ...
Dr Phoebe Phillips

Sarcoma and Nano-oncology

Group Leader : A/Prof Jia Lin Yang
The Sarcoma and Nano-oncology Group focuses on basic and translational studies to improve treatment of human sarcomas ...
Jia Lin Yang


Back to top